We hereby notify the change in the share capital of Sorin S.p.A. following the partial subscription of the capital increase for stock options exercise, approved by the Board of Directors on September 28^th, 2006.
 
The new share capital (entirely subscribed and paid-in), is Euro 473,658,644, composed by the same number of shares with a par value of Euro 1 each.
 
In accordance with Art. 2444 of the Italian Civil Code, the certification of the executed capital increase has been filed with Milan Company Register on April 20, 2011.

About Sorin Group
Sorin Group (www.sorin.com), is a global medical device company and a leader in the treatment of cardiovascular diseases. The Company develops, manufactures and markets medical technologies for cardiac surgery and for the treatment of cardiac rhythm disorders. With 3,700 employees worldwide, Sorin Group focuses on three major therapeutic areas that include: cardiopulmonary bypass (extracorporeal circulation and autotransfusion systems), cardiac rhythm management, and heart valve repair and replacement. Every year, over one million patients are treated with Sorin Group devices in more than 80 countries.
 
For more information, please visit: www.sorin.com, or contact:
 
Martine Konorski                                                             Francesca Rambaudi
Director, Corporate Communications                           Carla Vidra
Sorin Group                                                                        Investor Relations
Tel: +33 (0)1 46 01 33 78                                                Sorin Group
Mobile: +33 (0)6 76 12 67 73                                         Tel: +39 02 69969716
e-mail: martine.konorski@sorin.com                      e-mail: investor.relations@sorin.com
 

.pdf